M&A
Seven pharma trends for 2016
December 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing
What will be the key industry trends in 2016?Pricing pressures
M&A activity drives record year for pharma outsourcing deals
December 11, 2015Sales and Marketing Covance, M&A, MA, labcorp, outsourcing
A drastic increase pharma industry in M&A activity has propelled the value of pharmaceutical outsourcing deals from $9.9 billion in …
AstraZeneca acquires ZS Pharma for $2.7bn, announces Q3 results
November 6, 2015Medical Communications AstraZeneca, M&A, MA, ZS Pharma, ZS-9, acquisitions, financial results, hyperkalaemia, mergers
AstraZeneca has announced its acquisition of ZS Pharma for an all-cash total of $2.7 billion. In the latest mega-money deal …
Shire to acquire Dyax in $5.9 billion deal
November 2, 2015Manufacturing and Production, Research and Development, Sales and Marketing Dyax, M&A, MA, R&D, Shire, hereditary angioedema, rare disease
Shire has struck a deal to acquire the biotech firm Dyax for $5.9 billion, in order to acquire exclusive rights …
Pharma dominates global M&A activity
July 10, 2015Sales and Marketing M&A, MA, acquisitions, mergers, takeovers
Mergers and acquisitions in the pharma, medical and biotech sectors have hit the highest levels in nearly 15 years, a …
Horizon attempts a hostile $3bn Depomed takeover
July 9, 2015Manufacturing and Production, Research and Development, Sales and Marketing Depomed, M&A, MA, acquisitions, horizon, mergers, takeover
Dublin-based specialty pharmaceutical company Horizon has launched a bid to buy Depomed for $3 billion. Horizon, a biopharma company focussed …
Teva ‘to increase Mylan bid to $43bn’
July 7, 2015Sales and Marketing M&A, MA, Mylan, Teva, generics
Israeli drugmaker Teva is considering whether to up its bid for US rival firm Mylan, with reports that it could …
Mylan tells Teva to ‘stop playing games’ and make firm bid
June 2, 2015Manufacturing and Production, Sales and Marketing M&A, MA, Mylan, Teva, generics
Mylan has written another strongly-worded letter to Teva, this time accusing the Israeli firm of ‘playing games’ and violating US …
M&A drama continues as Mylan rejects Teva
April 28, 2015Sales and Marketing M&A, MA, Mylan, Perrigo, Teva, bids, generics, takeovers
Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned …
Hold your horses: M&A is about talent, not just pipelines
November 25, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, mergers, molloy, roik, rsa, talent
The morning mist is rising on the battlefield. At stake: the crown riches and glory of tomorrow’s pharma leadership. The …
Pressure on pharma M&A
January 7, 2013Research and Development, Sales and Marketing Ernst & Young, M&A, MA, mergers
The world’s largest pharma companies will be under greater pressure to merge with or purchase other firms over the next …
Termeer exit could help Sanofi
September 30, 2010Sales and Marketing Genzyme, M&A, MA, Sanofi
Genzyme’s chief executive Henri Termeer has signalled he will retire next year, a move which would help smooth the way …
Two $1 billion dollar acquisition deals go through
August 11, 2010Sales and Marketing Alcon, M&A, MA, Novartis, Ratiopharm, Teva
Two major acquisition deals mounted by Teva and Novartis are in their final stages as they move to complete potentially …
Astellas set to acquire OSI Pharmaceuticals for $4bn
May 17, 2010Research and Development, Sales and Marketing Astellas, M&A, MA, OSI
After four months and several failed bids Astellas Pharma has signed a definitive merger agreement with US biotech firm OSI …
Pharma mergers and acquisitions in 2009
December 22, 2009Research and Development, Sales and Marketing Abbott, GSK, J&J, JJ, M&A, MA, Novartis, Pfizer, Wyeth, generics, industry, merger, year in review
This year saw two ‘mega mergers’ in the sector, the acquisition of Wyeth by Pfizer and the reverse takeover of …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
